Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 11/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862434 | 0.86 | ACACB (0.40) | ACACBLMNAC5AR1TRPA1PTGS1 | |
| SCHEMBL19862435 | 0.80 | LMNA (0.40) | ACACBLMNAC5AR1TRPA1PTGS1 | |
| SCHEMBL17618323 | 0.77 | NOTUM (0.59) | ACACBTRPV3NOTUM | |
| SCHEMBL19365627 | 0.75 | MAP4K4 (0.44) | ACACBTRPV3MAP4K4 | |
| SCHEMBL12074844 | 0.73 | LMNA (0.52) | LMNAC5AR1TRPA1PTGS1CACNA1C | |
| SCHEMBL15187982 | 0.72 | HRH3 (0.46) | TRPV3LMNAMAPT | |
| SCHEMBL16939771 | 0.70 | LMNA (0.44) | LMNAC5AR1TRPA1PTGS1CACNA1C | |
| SCHEMBL22422339 | 0.69 | ADRB1 (0.54) | LMNA | |
| SCHEMBL14228296 | 0.69 | LMNA (0.46) | LMNATRPA1PTGS1CACNA1CMAPT | |
| SCHEMBL12257599 | 0.69 | HTT (0.42) | ACACBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACACB 344/4885TRPV3 4464/4885LMNA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.